Emerging research suggest Retatrutide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , could offer a significant step forward for obesity management . Early human trials have demonstrated impressive losses in body mass , possibly surpassing current weight-loss medications . However , more study is requi